 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...187188189190191192193194195196197...203204» |
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Surveillance of Humira in Korean JIA Patients (clinicaltrials.gov) - May 6, 2016
P=N/A, N=28, Completed, Sponsor: AbbVie
Recruiting --> Completed | N=600 --> 28
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - May 6, 2016
P3, N=217, Completed, Sponsor: AbbVie
Recruiting --> Completed | N=600 --> 28 Active, not recruiting --> Completed
- |||| etrolizumab (RG7413) / Roche
Trial primary completion date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - May 5, 2016
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Nov 2018 --> Mar 2018
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Real-world evidence, Real-world: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (clinicaltrials.gov) - May 3, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Nov 2018 --> Mar 2018 Initiation date: Feb 2016 --> May 2016
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P3 trial: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - May 3, 2016
P3, N=1575, Not yet recruiting, Sponsor: R-Pharm
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: AS PMOS: Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients (clinicaltrials.gov) - May 3, 2016
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Initiation date: Feb 2016 --> May 2016 Trial primary completion date: Mar 2017 --> Jul 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PASSION: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) (clinicaltrials.gov) - Apr 29, 2016
P=N/A, N=1036, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Mar 2017 --> Jul 2017 Active, not recruiting --> Completed
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
New trial: DLAC: "Drugs in Lactation" Analysis Consortium (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=300, Recruiting, Sponsor: The Hospital for Sick Children
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, P4 data, HEOR, Patient reported outcomes: Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) (clinicaltrials.gov) - Apr 26, 2016
P=N/A, N=387, Recruiting, Sponsor: AbbVie
- |||||||||| Cosentyx (secukinumab) / Novartis
New P3 trial, Monotherapy: EXCEED: Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (clinicaltrials.gov) - Apr 20, 2016
P3, N=852, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (clinicaltrials.gov) - Apr 16, 2016
P=N/A, N=670, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: May 2020 --> May 2018
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Complete-PS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (clinicaltrials.gov) - Apr 16, 2016
P=N/A, N=660, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: May 2020 --> May 2018 Trial primary completion date: Oct 2018 --> Jun 2017
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Complete-AS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (clinicaltrials.gov) - Apr 16, 2016
P=N/A, N=1120, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Oct 2018 --> Jun 2017 Trial primary completion date: Jul 2022 --> Jun 2018
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Apr 15, 2016
P3, N=422, Completed, Sponsor: Pfizer
Trial primary completion date: Jul 2022 --> Jun 2018 Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Apr 15, 2016
P3, N=50, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed N=200 --> 50 | Trial primary completion date: Oct 2017 --> Jun 2017
- Humira (adalimumab) / Eisai, AbbVie
New trial, HEOR: HOPE: Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=50, Recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial: SOTHIS: Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=540, Not yet recruiting, Sponsor: AbbVie
- Humira (adalimumab) / AbbVie
Trial initiation date, Trial primary completion date: HELP-AID: Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=140, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
N=200 --> 50 | Trial primary completion date: Oct 2017 --> Jun 2017 Initiation date: Jan 2016 --> Apr 2016 | Trial primary completion date: Jul 2018 --> Oct 2018
- || Humira (adalimumab) / AbbVie
Enrollment status, Patient reported outcomes: UCanADA: Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Initiation date: Jan 2016 --> Apr 2016 | Trial primary completion date: Jul 2018 --> Oct 2018 Enrolling by invitation --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Humira (adalimumab) / AbbVie
Trial initiation date: DIPIT: Diabetes Islet Preservation Immune Treatment (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=42, Not yet recruiting, Sponsor: Camillo Ricordi and Jay Skyler
Enrolling by invitation --> Recruiting Initiation date: Jan 2016 --> Jun 2016
- |||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Humira (adalimumab) / Eisai, AbbVie
Enrollment open: IMMvent: BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Mar 28, 2016
P3, N=600, Recruiting, Sponsor: Boehringer Ingelheim
Initiation date: Jan 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: AMORE: A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=60, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, HEOR, Real-world evidence, Adherence, Real-world: CONCORDIA: A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=280, Not yet recruiting, Sponsor: AbbVie
- || Xeljanz (tofacitinib) / Pfizer, Enbrel (etanercept) / Pfizer, Amgen
Clinical: Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 8, 2016
P4, N=4000, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2019 --> Aug 2019
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: COAST-V: A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Mar 2, 2016
P3, N=320, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Humira (adalimumab) / Eisai, AbbVie
New P3 trial: IMMvent: BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Feb 29, 2016
P3, N=600, Not yet recruiting, Sponsor: Boehringer Ingelheim
- Biomarker, Enrollment change, Trial primary completion date: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 26, 2016
P4, N=110, Recruiting, Sponsor: Medical University of Graz
Trial primary completion date: Apr 2019 --> Aug 2019 N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017
- |||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Trial primary completion date: Muscara: Doppler Evaluation in RA Patients After Adalimumab. (clinicaltrials.gov) - Feb 25, 2016
P4, N=120, Recruiting, Sponsor: Ronald van Vollenhoven, prof.
N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Feb 24, 2016
P4, N=107, Completed, Sponsor: Innovaderm Research Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / AbbVie
Enrollment closed: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Feb 23, 2016
P4, N=100, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (clinicaltrials.gov) - Feb 22, 2016
P=N/A, N=30, Recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Jul 2016
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial: AMORE: A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients (clinicaltrials.gov) - Feb 22, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: AbbVie
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=0, Withdrawn, Sponsor: AbbVie
Trial primary completion date: Apr 2016 --> Jul 2016 N=100 --> 0 | Initiation date: Nov 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2019 --> Feb 2020
- ||| remtolumab (ABT-122) / AbbVie
Enrollment closed, P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Feb 21, 2016
P2, N=220, Active, not recruiting, Sponsor: AbbVie
N=100 --> 0 | Initiation date: Nov 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2019 --> Feb 2020 Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> Apr 2015
- || atacicept (VT-001) / Vera Therap
Trial primary completion date: Atacicept in Anti-Tumor Necrosis Factor Alpha-na (clinicaltrials.gov) - Feb 17, 2016
P2, N=311, Completed, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> Apr 2015 Trial primary completion date: May 2009 --> Oct 2009
- ||||| Tremfya (guselkumab) / J&J
Enrollment closed: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Feb 17, 2016
P3, N=999, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2009 --> Oct 2009 Recruiting --> Active, not recruiting
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Feb 11, 2016
P4, N=916, Completed, Sponsor: UCB Pharma SA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
New trial: ENHANCE: Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis (clinicaltrials.gov) - Feb 8, 2016
P=N/A, N=100, Recruiting, Sponsor: European Georges Pompidou Hospital
- || Humira (adalimumab) / AbbVie
Trial primary completion date, MRI: PARADE: Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=90, Recruiting, Sponsor: Karolinska Institutet
Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> Dec 2016
- ||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Trial completion: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Feb 4, 2016
P3, N=1304, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2012 --> Dec 2016 Active, not recruiting --> Completed
- ||| Entyvio (vedolizumab) / Takeda
New trial: Entyvio PASS: Entyvio (Vedolizumab) Long Term Safety Study (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=5000, Recruiting, Sponsor: Takeda
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date, Monotherapy: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (clinicaltrials.gov) - Feb 4, 2016
P3, N=340, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Dec 2020
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, Real-world evidence, Real-world: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (clinicaltrials.gov) - Jan 29, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: AbbVie
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 29, 2016
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jan 2016 --> Dec 2020 Initiation date: Jan 2009 --> Sep 2009
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Jan 29, 2016
P=N/A, N=554, Active, not recruiting, Sponsor: University of California, San Diego
Initiation date: Jan 2009 --> Sep 2009 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Aug 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: AS PMOS: Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Aug 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, HEOR, Combination therapy: FOURIER: Adalimumab in the Treatment of Chronic Pouchitis (clinicaltrials.gov) - Jan 28, 2016
P3, N=13, Completed, Sponsor: Odense University Hospital
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | N=24 --> 13
- |||| Humira (adalimumab) / AbbVie
Trial primary completion date: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jan 28, 2016
P3, N=300, Recruiting, Sponsor: AbbVie
Recruiting --> Completed | N=24 --> 13 Trial primary completion date: Oct 2015 --> Jan 2017
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Observational data: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Oct 2015 --> Jan 2017 Recruiting --> Active, not recruiting